IDEAYA Biosciences, Inc. (IDYA): Price and Financial Metrics


IDEAYA Biosciences, Inc. (IDYA)

Today's Latest Price: $13.56 USD

0.20 (1.50%)

Updated Nov 27 1:00pm

Add IDYA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IDYA Stock Price Chart Interactive Chart >

Price chart for IDYA

IDYA Price/Volume Stats

Current price $13.56 52-week high $19.97
Prev. close $13.36 52-week low $2.95
Day low $13.50 Volume 38,500
Day high $13.71 Avg. volume 160,355
50-day MA $13.00 Dividend yield N/A
200-day MA $10.03 Market Cap 394.19M

IDEAYA Biosciences, Inc. (IDYA) Company Bio


IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


IDYA Latest News Stream


Event/Time News Detail
Loading, please wait...

IDYA Latest Social Stream


Loading social stream, please wait...

View Full IDYA Social Stream

Latest IDYA News From Around the Web

Below are the latest news stories about IDEAYA Biosciences Inc that investors may wish to consider to help them evaluate IDYA as an investment opportunity.

Ideaya and Pfizer to test doublet therapy in certain solid tumors

IDEAYA Biosciences (IDYA) expands its clinical trial collaboration and supply agreement with Pfizer (PFE) with a new study evaluating the combination of IDE196, a protein kinase inhibitor, and crizotinib, a cMET inhibitor, in patients with GNAQ or GNA11 mutation-positive solid tumors, including metastatic uveal melanoma ((MUM)), skin melanoma, lung cancer...

Seeking Alpha | September 24, 2020

IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket Trial

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that it has met the clinical protocol criteria for cohort expansion in the cutaneous (skin) melanoma cohort of its Phase 2 basket arm evaluating IDE196 monotherapy in solid tumors harboring GNAQ or GNA11 hotspot mutations (GNAQ/11).

Yahoo | July 16, 2020

IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the Company will participate in the following upcoming investor conferences:

Yahoo | July 14, 2020

Osmotica's FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

Osmotica Receives FDA Approval for Droopy Eyelid Treatment Osmotica Pharmaceuticals Plc (OSMT) reported that the FDA has given its approval for the company’s novel treatment for acquired blepharoptosis, or ptosis. Upneeq is now the only FDA-approved medical treatment for acquired blepharoptosis. One study involving adults over the age of 50...

Avisol Capital Partners on Seeking Alpha | July 13, 2020

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor

SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the Phase 1 combination study of IDE196…

PR Newswire | July 9, 2020

Read More 'IDYA' Stories Here

IDYA Price Returns

1-mo 9.80%
3-mo 16.30%
6-mo 32.55%
1-year 77.25%
3-year N/A
5-year N/A
YTD 80.80%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7963 seconds.